The Imbalanced Expression of Matrix Metalloproteinases in Nephrogenic Systemic Fibrosis PDF Print E-mail
Monday, 16 August 2010 10:23
Brent C. Kelly, MD, Leslie Scroggins Markle, MD, Jennifer L. Vickers, MD, Matthew S. Petitt, DO, Sharon S. Raimer, MD, and Catherine McNeese, MD

Background:
Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-b has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express a-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis.

Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples.

Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and a-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison.

Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for a-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin.

Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques.

Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation. ( J Am Acad Dermatol 2010;63:483-9.)

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Pulmonary Hypertension In Systemic Sclerosis

A.J. MacGregor, R. Canavan, C. Knight, C.P. Denton, J. Davar, J. Coghlan, and C.M. BlackPublished: 2001

» Beta-thymosins and Interstitial Lung Disease: Study of a Scleroderma Cohort with a One-year Follow-up

Beta-thymosins play roles in cytoskeleton rearrangement, angiogenesis, fibrosis and reparative process, thus suggesting a possible involvement in the pathogenesis of systemic sclerosis. The aim of the study was to investigate the presence of...

» Targeted Therapy for Systemic Sclerosis: How Close are We?

Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-AlmirallPosted: 09/14/2010; Nat Rev Rheumatol. 2010;6(5):269-278. © 2010 Nature Publishing GroupDespite recent etiopathogenetic advances, systemic sclerosis continues to be...

» FDA Approves New Lupus Drug

The FDA has approved (Benlysta) for reducing disease activity in (SLE), making it the first new lupus drug in more than 50 years. Belimumab is a monoclonal antibody targeting the B-lymphocyte stimulator protein, called BLyS. It was co-developed by...

» Subclinical Atherosclerosis Noted in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical , according to a study published online Aug. 16 in Arthritis Care & Research.To identify signs of early...

» Erectile Dysfunction Drug Could Improve Raynaud’s Symptoms Associated with Scleroderma

Adding tadalafil (Cialis®; Adcirca®) to the treatment of people with can improve ’s phenomenon symptoms and heal and prevent hand and finger associated with it, according to research presented this week at the American College of Rheumatology...